Drugs / KL-140
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03426371 | Mar 2018 → Nov 2021 | colorectal cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL-140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03426371 ↗ |
| Action | Inhibit | “Epidermal Growth Factor Receptor (EGFR) Antagonist” NCT03426371 ↗ |
| Target | EGFR | “Anti-EGFR Monoclonal Antibody” NCT03426371 ↗ |